ACHV

3.34

6.03% 0.19

Dopo l'orario di chiusura: 3.34

Achieve Life Sciences Inc (ACHV)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ACHV Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$3.15

Aprire:

$3.19

Volume 24 ore:

279.58K

Relative Volume:

1.43

Capitalizzazione di mercato:

$115.86M

Reddito:

Utile/perdita netta:

$-32.94M

Rapporto P/E:

-3.009

EPS:

-1.11

Flusso di cassa netto:

$-24.95M

1 W Prestazione:

+12.46%

1M Prestazione:

+38.02%

6M Prestazione:

-24.26%

1 anno Prestazione:

-37.45%

Intervallo 1D:

$3.1006

$3.4188

Intervallo di 1 settimana:

$2.89

$3.4188

Portata 52W:

$1.84

$5.58

Achieve Life Sciences Inc Stock (ACHV) Company Profile

Nome

Achieve Life Sciences Inc

Settore

Healthcare (1177)

Industria

Biotechnology (671)

Telefono

425-686-1500

Indirizzo

22722 29TH DR. SE, SEATTLE, BC

Dipendente

Cinguettio

Prossima data di guadagno

2025-03-11

Ultimi documenti SEC

ACHV's Discussions on Twitter

Confronta ACHV con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ACHV Achieve Life Sciences Inc	3.34	103.01M	0	-32.94M	-24.95M	-1.11
ONC Beone Medicines Ltd Adr	246.68	25.81B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	447.09	111.46B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.30	40.37M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	605.39	64.44B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	77.49	6.19B	0	-153.72M	-103.81M	-2.00

Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-11-14	Iniziato	Rodman & Renshaw	Buy
2024-09-27	Iniziato	Raymond James	Strong Buy
2023-05-10	Reiterato	Maxim Group	Buy
2021-06-23	Iniziato	Oppenheimer	Outperform

Achieve Life Sciences Inc Borsa (ACHV) Ultime notizie

May 28, 2025

Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference - GlobeNewswire

May 28, 2025

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Shares Purchased by Northern Trust Corp - Defense World

May 28, 2025

May 23, 2025

Shay Capital LLC Sells 425,000 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) - MarketBeat

May 23, 2025

May 20, 2025

ACHV: New Insights from ORCA-3 Study to Be Shared at 2025 Conference | ACHV Stock News - GuruFocus

May 20, 2025

Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake | ACHV Stock News - GuruFocus

May 20, 2025

Achieve Life Sciences to Present Phase 3 Study Findings on Cytisinicline for Smoking Cessation at 2025 ATS Conference - Nasdaq

May 20, 2025

Achieve Life Sciences to Present New Data at the 2025 ATS - GlobeNewswire

May 20, 2025

New Clinical Data Shows Cytisinicline Cuts Nicotine Cravings in Phase 3 Trial | ACHV Stock News - Stock Titan

May 20, 2025

May 18, 2025

Brokers Offer Predictions for ACHV Q3 Earnings - Defense World

May 18, 2025

May 16, 2025

Tower Research Capital LLC TRC Acquires 4,905 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World

May 16, 2025

What is Zacks Small Cap’s Estimate for ACHV Q2 Earnings? - Defense World

May 16, 2025

May 15, 2025

Achieve Life Sciences targets NDA submission for cytisinicline in June 2025 as open label study hits key milestones - MSN

May 15, 2025

May 14, 2025

Raymond James Financial Inc. Purchases New Position in Achieve Life Sciences, Inc. (NASDAQ:ACHV) - MarketBeat

May 14, 2025

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q1 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025

ACHV: Kicking Butts to Achieve June NDA Filing - Yahoo Finance

May 14, 2025